The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase

N. Lytvynenko (Kyiv, Ukraine)

Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Session: Paediatric TB: MDRTB (II)
Session type: Thematic Poster
Number: 2761
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Lytvynenko (Kyiv, Ukraine). The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase. 2761

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Year: 2017



Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB
Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases
Year: 2021


Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019

Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB
Source: Eur Respir J 2013; 41: 1386-1392
Year: 2013



Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016


Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children
Source: Eur Respir J, 57 (1) 2001756; 10.1183/13993003.01756-2020
Year: 2021



First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB
Source: Eur Respir J 2016; 47:1581-1584
Year: 2016


Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Source: Eur Respir J 2015; 45: 161-170
Year: 2015



Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Source: Eur Respir J 2016; 47:1591-1592
Year: 2016


Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


A prospective study of prevalence of adverse drug reactions to the short course anti-tuberculosis regimen in Korea
Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control
Year: 2007


Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019


Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 143s
Year: 2003

Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008


Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen
Source: Annual Congress 2012 - Tuberculosis: clinical findings I
Year: 2012

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
Source: Eur Respir J 2012; 40: 1430-1442
Year: 2012



One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 618s
Year: 2004

A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001

Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021


Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study
Source: Eur Respir J, 49 (5) 1700387; 10.1183/13993003.00387-2017
Year: 2017